LIVIVO - Search results -

Search results

Result 1 - 8 of total 8

Search options

Article ; Online: Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis.

Caron, Bénédicte / Reimund, Jean-Marie / Ben Abdelghani, Meher / Sondag, Daniel / Noirclerc, Monique / Duclos, Bernard / Kurtz, Jean-Emmanuel / Nguimpi-Tambou, Marlène

Pancreas

2021 Volume 50, Issue 6, Page(s) 803–806

Abstract: Objectives: The use of FOLFIRINOX (a combination of oxaliplatin, irinotecan, fluorouracil, and leucovorin) is one of the therapeutic standards in pancreatic adenocarcinoma. We analyzed progression-free survival (PFS) and overall survival (OS) and their ... ...

Abstract	Objectives: The use of FOLFIRINOX (a combination of oxaliplatin, irinotecan, fluorouracil, and leucovorin) is one of the therapeutic standards in pancreatic adenocarcinoma. We analyzed progression-free survival (PFS) and overall survival (OS) and their predictive factors in patients treated with FOLFIRINOX as first-line therapy in metastatic pancreatic cancer. Methods: This multicenter retrospective analysis included patients treated with FOLFIRINOX between 2011 and 2015. The Kaplan-Meier method was used to estimate OS and PFS. The statistical comparison for survival was performed by the log-rank test. Predictive factors were estimated in multivariate analysis with the use of a Cox model. Results: One hundred and thirty-six patients were included (74 men, 62 women; median age, 62 years [range, 29-74 years]). The median PFS was 5.97 months (95% confidence interval, 4.4-6.63 months). The median OS was 8.93 months (95% confidence interval, 7.4-10.07 months). Prognostic factors in multivariate analysis were the use of granulocyte colony-stimulating factor, which appeared to be a good prognostic factor. Dose intensity of oxaliplatin (≥74.48%) and dose intensity of bolus of fluorouracil (>6.9%) appeared as pejorative factors. Conclusions: In patients with metastatic pancreatic adenocarcinoma treated with FOLFIRINOX in first line, dose modifications at the onset of adverse effects and early use of granulocyte-colony stimulating factor seem to be associated with a better survival.
MeSH term(s)	Adenocarcinoma/drug therapy ; Adenocarcinoma/pathology ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Humans ; Irinotecan/administration & dosage ; Irinotecan/adverse effects ; Kaplan-Meier Estimate ; Leucovorin/administration & dosage ; Leucovorin/adverse effects ; Male ; Middle Aged ; Multivariate Analysis ; Nausea/chemically induced ; Neoplasm Metastasis ; Neutropenia/chemically induced ; Outcome Assessment, Health Care/methods ; Outcome Assessment, Health Care/statistics & numerical data ; Oxaliplatin/administration & dosage ; Oxaliplatin/adverse effects ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/pathology ; Prognosis ; Retrospective Studies ; Vomiting/chemically induced
Chemical Substances	Oxaliplatin (04ZR38536J) ; Irinotecan (7673326042) ; Leucovorin (Q573I9DVLP) ; Fluorouracil (U3P01618RT)
Language	English
Publishing date	2021-08-02
Publishing country	United States
Document type	Journal Article ; Multicenter Study
ZDB-ID	632831-3
ISSN	1536-4828 ; 0885-3177
ISSN (online)	1536-4828
ISSN	0885-3177
DOI	10.1097/MPA.0000000000001837
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2160: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma.

Grave, Athénaïs / Blanc, Julie / De Bari, Berardino / Pernot, Mandy / Boulbair, Fatiha / Noirclerc, Monique / Vienot, Angélique / Kim, Stefano / Borg, Christophe / Boustani, Jihane

Frontiers in oncology

2022 Volume 12, Page(s) 918271

Abstract: Introduction: The incidence of metastatic squamous cell carcinoma of the anus (SCCA) is increasing. Even if systemic docetaxel, cisplatin, and 5-Fluorouracil (DCF) provide a high rate of long-term remission, the role of pelvic chemoradiation (CRT) is ... ...

Abstract	Introduction: The incidence of metastatic squamous cell carcinoma of the anus (SCCA) is increasing. Even if systemic docetaxel, cisplatin, and 5-Fluorouracil (DCF) provide a high rate of long-term remission, the role of pelvic chemoradiation (CRT) is unknown in this setting. We reported the safety and efficacy of local CRT in patients with synchronous metastatic SCCA who achieved objective response after upfront DCF. Methods: Patients included in Epitopes HPV01 or Epitopes HPV02 or SCARCE trials and treated with DCF followed by pelvic CRT were included. Concurrent chemotherapy was based on mitomycin (MMC) (10 mg/m² for two cycles) and fluoropyrimidine (capecitabine 825 mg/m² twice a day at each RT treatment day or two cycles of intra-venous 5FU 1000 mg/m² from day 1 to day 4). Primary endpoints were safety, local complete response rate, and local progression-free survival (PFS). Secondary endpoints were PFS, overall survival (OS), and metastasis-free survival (MFS). Results: From 2013 to 2018, 16 patients received DCF followed by a complementary pelvic CRT for advanced SCCA. Median follow-up was 42 months [range, 11-71]. All patients received the complete radiation dose. Compliance to concurrent CT was poor. Overall, 13/15 of the patients (87%) had at least one grade 1-2 acute toxicity and 11/15 of the patients (73%) had at least one grade 3-4 toxicity. There was no treatment-related death. The most frequent grade 3-4 adverse effects were neutropenia (36%), dermatitis (40%), and anitis (47%). Eleven patients (73%) had at least one chronic grade 1 or 2 toxicity. One patient had a grade 4 chronic rectitis (7%). Complete local response rate was 81% at first evaluation and 62.5% at the end of the follow-up. Median local PFS was not reached and the 3-year local PFS was 77% (95%CI 76.8-77). Conclusions: In patients with metastatic SCCA who had a significant objective response after upfront DCF, local CRT was feasible with high complete local response rate. The good local control rate, despite interruptions due to toxicities and low CT compliance, underline the role of pelvic RT. The high rate of toxicity prompts the need to adapt CRT regimen in the metastatic setting.
Language	English
Publishing date	2022-07-22
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2022.918271
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Organisation d’un service de radiothérapie pendant l’épidémie de COVID-19 : expérience du centre hospitalier de Mulhouse

Ohnleiter, Thomas / Piot, Luc / Rogenmuser, Agathe / Noirclerc, Monique / Hamlaoui, Rabah / Grandgirard, Alain

Cancer/Radiothérapie

Abstract: Résumé L’épidémie de COVID-19 continue de croître de manière exponentielle dans notre pays. Si la majorité des formes sont bénignes, les patients atteints de cancer sont à risque de voir se développer une forme grave de la maladie. Les services de ... ...

Abstract	Résumé L’épidémie de COVID-19 continue de croître de manière exponentielle dans notre pays. Si la majorité des formes sont bénignes, les patients atteints de cancer sont à risque de voir se développer une forme grave de la maladie. Les services de radiothérapie sont un lieu à potentiel de contamination en raison du nombre de patients traités et de personnels présent. Leur organisation pendant la période épidémique vise à assurer la continuité des soins tout en limitant le risque de décès dû à une contamination par le SARS-CoV-2 (virus responsable de la COVID-19). Dans le service de radiothérapie du groupe hospitalier de la région de Mulhouse et Sud-Alsace, cette organisation s’articule en cinq points : la protection des personnels médicaux et paramédicaux, la protection des patients en cours de traitement, la détection des patients suspects d’être atteints de COVID-19 et leur prise en charge, la réorganisation du circuit patient et les mesures concernant l’organisation du système qualité du service. Nos pistes de réflexion, débutée dès le début de l’épidémie dans notre département, nous permettent de préserver au maximum l’accès aux soins radiothérapiques en anticipant le risque de diffusion du virus. Grâce à des réunions bihebdomadaires, nous continuons à nous adapter à l’évolution épidémique dans notre service, en tenant compte de nos moyens matériels. La possibilité de réaliser des tests de diagnostic chez tous les patients suspects nous permettrait également d’affiner nos procédures. Summary The COVID-19 outbreak grows exponentially in our country. Despite most of patients develops benign symptoms, cancer patients are at risk of a severe form of the disease. Radiotherapy centres are a potential contamination place due to the number of patients treated and staff present. Their organization during the outbreak period aims to ensure continuity of care while limiting the risk of death from COVID-19. In the radiotherapy department of Mulhouse hospital (France), we pointed five points out: protection of medical and paramedical staff, protection of patients undergoing treatment, detection of patients suspected of being infected by SARS-CoV-2 and their management, reorganization of the patient circuit and measures regarding the quality management. This reflection, which began at the beginning of the outbreak in our city, allows us to preserve the access to radiotherapy treatments by anticipating the risk of spreading the virus. Through biweekly meetings, we continue to adapt to the epidemic in our department, considering our material resources. The ability to perform diagnostic tests in all suspect patients would also allow us to refine our procedures.
Keywords	covid19
Publisher	Elsevier
Document type	Article ; Online
DOI	10.1016/j.canrad.2020.04.002
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Preoperative treatment combining capecitabine with radiation therapy in rectal cancer: a GERCOR Phase II Study.

Dupuis, Olivier / Vie, Brigitte / Lledo, Gérard / Hennequin, Christophe / Noirclerc, Monique / Bennamoun, Mohamed / Jacob, Jacques H

Oncology

2007 Volume 73, Issue 3-4, Page(s) 169–176

Abstract: Objective(s): To assess efficacy and tolerability of preoperative capecitabine chemoradiation in rectal cancer.: Methods: Patients received radiotherapy 45 Gy in 25 fractions over 5 weeks and capecitabine 825 mg/m(2) twice daily throughout ... ...

Abstract	Objective(s): To assess efficacy and tolerability of preoperative capecitabine chemoradiation in rectal cancer. Methods: Patients received radiotherapy 45 Gy in 25 fractions over 5 weeks and capecitabine 825 mg/m(2) twice daily throughout radiotherapy. Surgery was performed 5-7 weeks after radiotherapy. The primary endpoint was pathological complete response, secondary endpoints were downstaging and tolerability. Results: Fifty-one patients were enrolled in a phase II study, median age 62 years (range 35-78). Sixty-three percent of tumours involved the lower third of the rectum, 45% were fixed. The median delivered radiotherapy dose was 44.8 Gy (range 39.6-45.0 Gy) over 33-49 days. The treatment-related grade 3 adverse events were diarrhoea (12%), skin reactions (8%) and asthenia (8%), with no grade 4 toxicity. Fifty patients underwent surgery (29 conservative) and 1 patient refused. The pathological complete response rate was 20% and a further 10% of patients had minimal residual disease. Additional tumour downstaging was seen in 28% of patients and the sphincter preservation rate was 58%. Conclusions: Preoperative capecitabine chemoradiation is well tolerated and its efficacy supports further exploration, both as a single agent and as part of new therapeutic strategies.
MeSH term(s)	Adenocarcinoma/drug therapy ; Adenocarcinoma/radiotherapy ; Adenocarcinoma/secondary ; Adenocarcinoma/therapy ; Adult ; Aged ; Antimetabolites, Antineoplastic/therapeutic use ; Capecitabine ; Combined Modality Therapy ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/therapeutic use ; Female ; Fluorouracil/analogs & derivatives ; Fluorouracil/therapeutic use ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Prodrugs/therapeutic use ; Radiotherapy Dosage ; Rectal Neoplasms/drug therapy ; Rectal Neoplasms/pathology ; Rectal Neoplasms/radiotherapy ; Rectal Neoplasms/therapy ; Survival Rate
Chemical Substances	Antimetabolites, Antineoplastic ; Prodrugs ; Deoxycytidine (0W860991D6) ; Capecitabine (6804DJ8Z9U) ; Fluorouracil (U3P01618RT)
Language	English
Publishing date	2007
Publishing country	Switzerland
Document type	Clinical Trial, Phase II ; Journal Article ; Multicenter Study
ZDB-ID	250101-6
ISSN	1423-0232 ; 0030-2414
ISSN (online)	1423-0232
ISSN	0030-2414
DOI	10.1159/000127383
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.151: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Preoperative Treatment Combining Capecitabine with Radiation Therapy in Rectal Cancer: A GERCOR Phase II Study

Dupuis, Olivier / Vie, Brigitte / Lledo, Gérard / Hennequin, Christophe / Noirclerc, Monique / Bennamoun, Mohamed / Jacob, Jacques H.

Oncology

2008 Volume 73, Issue 3-4, Page(s) 169–176

Abstract: Objective(s): To assess efficacy and tolerability of preoperative capecitabine chemoradiation in rectal cancer. Methods: Patients received radiotherapy 45 Gy in 25 fractions over 5 weeks and capecitabine 825 mg/m2 twice daily throughout radiotherapy. ... ...

Institution	Clinique Victor Hugo, Le Mans Centre F. Baclesse, Caen Clinique St Jean, Lyon Hôpital St Louis, Paris Centre Hospitalier, Mulhouse, et Hôpital Le Raincy, Montfermeil, France
Abstract	Objective(s): To assess efficacy and tolerability of preoperative capecitabine chemoradiation in rectal cancer. Methods: Patients received radiotherapy 45 Gy in 25 fractions over 5 weeks and capecitabine 825 mg/m2 twice daily throughout radiotherapy. Surgery was performed 5–7 weeks after radiotherapy. The primary endpoint was pathological complete response, secondary endpoints were downstaging and tolerability. Results: Fifty-one patients were enrolled in a phase II study, median age 62 years (range 35–78). Sixty-three percent of tumours involved the lower third of the rectum, 45% were fixed. The median delivered radiotherapy dose was 44.8 Gy (range 39.6–45.0 Gy) over 33–49 days. The treatment-related grade 3 adverse events were diarrhoea (12%), skin reactions (8%) and asthenia (8%), with no grade 4 toxicity. Fifty patients underwent surgery (29 conservative) and 1 patient refused. The pathological complete response rate was 20% and a further 10% of patients had minimal residual disease. Additional tumour downstaging was seen in 28% of patients and the sphincter preservation rate was 58%. Conclusions: Preoperative capecitabine chemoradiation is well tolerated and its efficacy supports further exploration, both as a single agent and as part of new therapeutic strategies.
Keywords	Rectal cancer ; Chemoradiation ; Capecitabine
Language	English
Publishing date	2008-04-16
Publisher	S. Karger AG
Publishing place	Basel, Switzerland
Document type	Article
Note	Clinical Study
ZDB-ID	250101-6
ISSN	1423-0232 ; 0030-2414
ISSN (online)	1423-0232
ISSN	0030-2414
DOI	10.1159/000127383
Database	Karger publisher's database

In stock of ZB MED Cologne/Königswinter

Uh III Zs.151: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Preoperative Treatment Combining Capecitabine with Radiation Therapy in Rectal Cancer: A GERCOR Phase II Study

Dupuis, Olivier / Vie, Brigitte / Lledo, Gérard / Hennequin, Christophe / Noirclerc, Monique / Bennamoun, Mohamed / Jacob, Jacques H.

Oncology - International Journal of Cancer Research and Treatment

2007 Volume 73, Issue 3-4, Page(s) 169–176

Abstract	Objective(s): To assess efficacy and tolerability of preoperative capecitabine chemoradiation in rectal cancer. Methods: Patients received radiotherapy 45 Gy in 25 fractions over 5 weeks and capecitabine 825 mg/m2 twice daily throughout radiotherapy. Surgery was performed 5-7 weeks after radiotherapy. The primary endpoint was pathological complete response, secondary endpoints were downstaging and tolerability. Results: Fifty-one patients were enrolled in a phase II study, median age 62 years (range 35-78). Sixty-three percent of tumours involved the lower third of the rectum, 45% were fixed. The median delivered radiotherapy dose was 44.8 Gy (range 39.6-45.0 Gy) over 33-49 days. The treatment-related grade 3 adverse events were diarrhoea (12%), skin reactions (8%) and asthenia (8%), with no grade 4 toxicity. Fifty patients underwent surgery (29 conservative) and 1 patient refused. The pathological complete response rate was 20% and a further 10% of patients had minimal residual disease. Additional tumour downstaging was seen in 28% of patients and the sphincter preservation rate was 58%. Conclusions: Preoperative capecitabine chemoradiation is well tolerated and its efficacy supports further exploration, both as a single agent and as part of new therapeutic strategies.
Keywords	Chemoradiation ; Capecitabine ; Rectal cancer
Language	English
Publisher	S. Karger AG
Publishing place	Basel
Publishing country	Switzerland
Document type	Article ; Online
ZDB-ID	250101-6
ISSN	1423-0232 ; 0030-2414 ; 0030-2414
ISSN (online)	1423-0232
ISSN	0030-2414
DOI	10.1159/000127383
Database	Karger publisher's database

In stock of ZB MED Cologne/Königswinter

Uh III Zs.151: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Phase II study of leucovorin, 5-fluorouracil and gemcitabine for locally advanced and metastatic pancreatic cancer (FOLFUGEM 2).

André, Thierry / Noirclerc, Monique / Hammel, Pascal / Meckenstock, Roderich / Landi, Bruno / Cattan, Stéphane / Selle, Frédéric / Codoul, Jean-François / Guerrier-Parmentier, Béatrice / Mokhtar, Rabia / Louvet, Christophe

Gastroenterologie clinique et biologique

2004 Volume 28, Issue 8-9, Page(s) 645–650

Abstract: Aim: FOLFUGEM 1 (leucovorin 400 mg/m2 combined with 5-flurorouracil (FU) bolus 400 mg/m2 then 5-FU 2-3 g/m2/46 hours and gemcitabine 1000 mg/m2 in 30 min) in patients with locally-advanced and metastatic pancreatic adenocarcinoma appeared to be toxic ( ... ...

Abstract	Aim: FOLFUGEM 1 (leucovorin 400 mg/m2 combined with 5-flurorouracil (FU) bolus 400 mg/m2 then 5-FU 2-3 g/m2/46 hours and gemcitabine 1000 mg/m2 in 30 min) in patients with locally-advanced and metastatic pancreatic adenocarcinoma appeared to be toxic (neutropenia and alopecia). The aims of this phase II multicentric study were to evaluate the response rate, clinical benefit and tolerance of a new scheme of combined leucovorin, 5-FU and gemcitabine (FOLFUGEM 2). Patients and methods: FOLFUGEM 2 associated leucovorin 400 mg/m2 in 2 hours followed by 5-FU 1000 mg/m2 in 22 hours, then gemcitabine 800 mg/m2 (10 mg/m2/min) with cycles every 14 days. Gemcitabine dose could be increased (1000 then 1250 mg/m2) when NCI/CTC toxicity was < or = grade 2. Results: Fifty-eight patients were included (locally-advanced tumor: N = 13 and metastatic: N = 45). Among the 39 patients with measurable disease, 11 had partial response (28.2%, 95% confidence interval: 14-42%) and 11 had stable disease (28.2%). On an intent-to-treat analysis, the objective response rate was 19% (95% confidence interval: 9-29%). Clinical benefit rate was 46%. Median progression-free survival and median overall survival were 3.1 and 7.2 months, respectively. There were 13% grade 3-4 neutropenia and 36% complete alopecia. Conclusion: FOLFUGEM 2 schema has an antitumoral effect in advanced pancreatic cancer and has an acceptable toxicity which appears to be less than that of FOLFUGEM 1.
MeSH term(s)	Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/therapeutic use ; Drug Therapy, Combination ; Female ; Fluorouracil/therapeutic use ; Humans ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/pathology ; Prospective Studies
Chemical Substances	Deoxycytidine (0W860991D6) ; Leucovorin (Q573I9DVLP) ; Fluorouracil (U3P01618RT)
Language	English
Publishing date	2004-08
Publishing country	France
Document type	Clinical Trial ; Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Review
ZDB-ID	752002-5
ISSN	0399-8320
ISSN	0399-8320
DOI	10.1016/s0399-8320(04)95042-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1346: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 19: Show issues
Zs.MN 1: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment

Lièvre, Astrid / Turpin, Anthony / Ray-Coquard, Isabelle / Le Malicot, Karine / Thariat, Juliette / Ahle, Guido / Neuzillet, Cindy / Paoletti, Xavier / Bouché, Olivier / Aldabbagh, Kais / Michel, Pierre / Debieuvre, Didier / Canellas, Anthony / Wislez, Marie / Laurent, Lucie / Mabro, May / Colle, Raphael / Hardy-Bessard, Anne-Claire / Mansi, Laura /

Colomba, Emeline / Bourhis, Jean / Gorphe, Philippe / Pointreau, Yoann / Idbaih, Ahmed / Ursu, Renata / Di Stefano, Anna Luisa / Zalcman, Gérard / Aparicio, Thomas / Moulin, Solenne / Leleu, Olivier / Leparree, Sylvie / Goasdoue, Henri / Piprot, Christine / Tourneur, Gerald / Bayart, Vincent / Lignier, Delphine / Lachaier, Emma / Khamari, Marwa / Coutte, Alexandre / Siembida, Nicolas / Houessinon, Aline / Regimbeau, Jean Marc / Chauffert, Bruno / Moreira, Aurélie / Hautefeuille, Vincent / Hee, Christine / Boone, Mathieu / Bihan, Céline / Chive, Emilie / Poulet-Potriquier, Stéphane / Fahem, Rachida / Luet, Dominique / Roquin, Guillaume / Vitellius, Carole / Cornet-Trichereau, Nathanaëlle / Caroli-Bosc, François-Xavier / Thirot-Bidault, Anne / Ropert, Stanislas / Gachet - Masson, Julie / Dehais, Mélanie / L'helgoualc'h, Gwen-Ael / Ali-Mahamadou, Ibrahim / Talfi, Safia / Belmont, Laure / Kilendo, Dieudonné / Benrezzak, Nasro / Dubief, Emeline / Conroy, Guillaume / Delique, Laurence / Basso, Maud / Pons, Isabelle / Salignon, Karine / Villing, Anne-Laure / Mougenot, Emmanuelle / Porebski, Cassandra / Guiatni, Asma / Cloarec, Nicolas / Mineur, Laurent / Bouchaud, Marie / David, Céleste / Peytier, Annie / Greletty, Thomas / Audemar, Franck / Vignes, Emanuelle / Minne, Floriane / Goldzak, Guillaume / Huysman, Fabienne / Hocine, Fayçal / Lakkis, Zaher / Meynard, Guillaume / Almotlak, Hamadi / Klajer, Elodie / Sun, Xu-Shan / Wasselin, Julie / Catala, Pascale / Mazuy, Claire / Vandamme, Hélène / Prevost, Jean-Briac / Fadin, Aurélie / Basson, Laurent / Huguet, Jean-Baptiste / Dos Santos, Emmanuelle / Jany, Bérangère / Saad, Alain / Goutorbe, Frédéric / Oziol, Eric / Ramdani, Mohamed / Kadiri, Ouafae / Garbay, Delphine / Huet, Clotilde / Giroux Leprieur, Etienne / Teng, Wen / Monvoisin, Justine / Arnaud Coffin, Patrick / Roux, Sylvie / Orfeuvre, Hubert / Chagros, Mélanie / Pillon, Didier / Rassoul, Agathe / Poureau, Pierre Guillaume / Novello, Cécile / Ducray, François / Trouba, Cécile / Bastit, Vianney / Babin, Emmanuel / Leon, Vincent / Courtecuisse, Anne-Catherine / Vambre, Julie / Tack, Vincent / Desauw, Christophe / Meniai, Fatima / Peres, Christina / Esparcieux, Aurélie / Perrier, Hervé / Doux, Nathalie / Kaphan, Régis / Roques, Bertrand / Rebischung, Christine / Mille, Dominique / Fernandes, Gaëlle / Abdelli, Naceur / Jousset, Natacha / Combe, Pierre / Jonveaux, Eric / Dumont, Patrick / Kanaan, Marc / Berthelot Gras, Corinne / Panis, Valérie / Kaluzinski, Laure / Venant-Valery, Marjolène / Lam, You-Heng / Vallee, Laura / Riviere, Frédéric / Durand, Muriel / Benghadid, Dihya / Villeneuve, Emilie / Hentic Dhome, Olivia / Bounouar, Zedjiga / De Mestier, Louis / Dubois, Jacqueline / Eyriey, Magali / Moreau, Lionel / Baihas, Dib / Aldabbagh, Kaïs / Degriffolet, Dominique / Sebbagh, Virginie / Seghezzi, Jean-Christophe / Lozach-Brugirard, Marion / Mandrou, Julie / Mavier, Loubna / Hennetier, Florence / Wagner, Jean-Philippe / Carola, Elisabeth / Chandirakumaran, Karthiga / Loutski, Sandrine / Cojean-Zelek, Isabelle / Bouras, Amina / Lacour, Sandrine / Froura, Fahem / Ben Nadji, Hadjer / Cattelain, Sophie / Darloy, Franck / Jolimoy Boilleau, Geneviève / Maissiat, Cyrielle / Darut-Jouve, Ariane / Lorgis, Véronique / Charifi-Alaoui, Ikram / Ghiringhelli, François / Drouillard, Antoine / Chaix, Marie / Manfredi, Sylvain / Lepage, Côme / Gagnaire, Alice / Latournerie, Marianne / jourdan, Sofia / Perrot, Nora / folia, Mireille / Minello, Anne / Jouve, Jean-Louis / Fery, Marielle / Landau, Alain / Evrard, Diane / Valenza, Bruno / Paitel, Jean-François / Chablais, Laetitia / Kreitmann, Thomas / Lancry-Lecomte, Laurence / Monard, Adrien / Faugeras, Eve / Boucheret, Paul / Glommeau, Cécile / Tchikladze, Christine / Garnier Tixidre, Claire / Long, Jérôme / Zaidi, Manel / Delabarre, Véronique / Meyzenc, Juliette / Ferrand, Loïc / Moro-Sibilot, Denis / Bouheret, Paul / Leyronnas, Cécile / Herve, Camille / Thoor, Audrey / Jacquet, Emanuelle / Roth, Gaël / Madapathage-Senanyake, Videsheka / Chupeau, Peggy / Bieber, Elsa / Rosso, Maud / Lepage, Isabelle / Priou, Frank / Laly, Margot / Aprelon, Sylvie / Sobolak, Natacha / Homokos, Helen / Watelle, Fabienne / Pham-Becker, Alice / Lauridant, Géraldine / Dujardin, Charlotte / Lenglin, Etienne / Nienguet Tsota, Aimée / Dominguez, Sophie / Forestier, Alexandra / Nouvel, Franck / Lerooy, Justine / Ratajczak, Céline / Romano, Olivier / Brzyski, Dorothéee / Barriere, Aurélien / Genet, Dominique / Tisse, Julien / Zasadny, Xavier / Grelet, Adeline / Hennion-Imbault, Amélie / Haustraete, Eglantine / Louafi, Samy / Awad, Manal / Zekri, Younes / Cheneau, Caroline / Leissen, Nolwen / Egreteau, Joëlle / Breant, Alexandra / Sarabi, Matthieu / Labonne, Stéphanie / Forestier, Julien / Leclercq, Céline / Prunier-Bossion, Florence / Ray Coquard, Isabelle / Guillet, Marielle / Theillaumas, Aurélie / Prome, Emilie / Walter, Thomas / Philouze, Pierre / Lawo, Melody / De Talhouet, Solène / Beuvelot, Johanne / Molin, Yann / Bellecoste Martin, Marie / Saussereau, Maud / Agnelli, Lauren / Fakhry, Nicolas / Laplace, Christophe / Norguet Monnereau, Emmanuelle / Boucard, Céline / Djenad, Kahina / Fontaine, Catherine / Seitz, Jean-François / Dahan, Laétitia / Sigrand, Julie / Duluc, Muriel / Locher, Christophe / Fleury, Marjory / Brou Marie, Ange / Berkane, Ramdane / Poupblanc, Séverine / Auby, Dominique / Petran, Daniela / Texereau, Patrick / Guerineau, Elodie / Andre, Morgan / Mahjoubi, Linda / Sarrazin, Fanny / Jeanson, Sonia / Gschwend, Anthony / Birr, Virginie / Fore, Mathieu / Noirclerc, Monique / Dahou, Sihem / Spaeth, Dominique / Lambotin, Mélanie / Lelu, Thomas / Linot, Benjamin / Hugon, Nathalie / Rousseau, Dominique / Castanie, Hélène / Lenne, Carole / Lortholary, Alain / Cessot, Anatole / Merzoug, Messaouda / Naudin, Cécile / Vannetzel, Jean-Michel / Aziz, Ghina / Hadj Arab, Yacine / Pernes, Stéphanie / Roche-Lachaise, Isabelle / Fiteni, Frédéric / Yahiaoui, Hadjer / Marel Lopez, Gwendoline / Oddoz, Jeanne / Peira, Fabienne / Michel, Olivier / Meunier, Jérôme / Ouahrani, Brahim / Roger, Antoine / Branco, Sonia / Nguyen, Van / Gisselbrecht, Mathilde / Hammad, Ghania / Mordant, Pierre / Stroksztejn, Magda / Pocard, Marc / Nlo Meyengue, Luc / Sacco, Emmanuelle / Simon Anne, Sophie / Fabre-Guillevin, Elizabeth / Slim, Marine / Zaanan, Aziz / Cadranel, Jacques / Pluvy, Johan / Ursu, Rénata / Geraldo, Amyrath / Lihi, Rime / Vo, Maryline / Brouk, Zohra / Colle, Raphaël / Bennamoun, Mostefa / Lacan, Fabrice / Louvet, Christophe / Mebarki, Soraya / Veyri, Marianne / Paillaud, Elena / Lucas, Christelle / Dubreuil, Olivier / Lyamani, Jamila / Agguini, Hanane / Soularue, Emilie / Jourdaine, Clément / Verillaud, Benjamin / Herzine, Hakima / Raymond, Eric / Mathiot, Nathalie / Palmieri, Lola Jade / Epanya, Christian / Taieb, Julien / Bertrand, Eliane / Goujon, Gaël / Namour, Céline / Gazeau, Benoit / Zafirova, Biljana / Mirghani, Haitham / Belin, Catherine / Belkhir, Kahina / Gharib, Myriam / Vozy, Aurore / Amrane, Karim / Spano, Jean-Philippe / Wassermann, Johanna / Feuvret, Loic / Bachet, Jean-Baptiste / Philonenko, Sara / Guillot, Laetitia / Zabbe, Marion / Gibiat, Stéphanie / Baylot, Camille / Jouinot, Aude / Leduc, Nicolas / Vieillot, Sabine / James, Laurie / Ducerf, Camille / Blanc, Jean-Frédéric / Falandry Leger, Claire / Wautot, Virginie / Chauvenet, Marion / Vincent, Aude / Tougeron, David / Goulvent, Sandrine / Suc, Etienne / Laurenty, Anne-Pascale / Marquis, Eric / Bonnaire, Margaux / Dewolf, Maxime / Brenet, Esteban / Billard, Delphine / Litre, Claude-Fabien / Dumazet, Antoine / Botsen, Damien / Vazel, Marion / Carlier, Claire / Bonnerave, David / Marchand-Crety, Charles / Bouche, Olivier / Fosse, Patricia / Sefrioui, David / Watson, Sarah / Torche, Fatah / Muron, Thierry / Natur, Stéphane / Desgrippes, Romain / Bihel, Véronique / Ferrand, François-Régis / Leiterer, Caroline / Lavole, Julie / Moquet, Claire / Pressoir, Nathalie / Dziukala, Catherine / Ligeza Poisson, Catherine / Naji, Abdelhalim / Williet, Nicolas / Phelip, Jean-Marc / Di Palma, Fabrice / Kherrour Mehdi, Amina / Langrand-Escure, Julien / Fournel, Pierre / Pigne, Grégoire / Saban-Roche, Léa / Magne, Nicolas / Vassal, Cécile / Jacquin, Jean-Philippe / Ramirez, Carole / Vallard, Alexis / Collard, Olivier / Rivoirard, Romain / Graber, Ivan / Trager Maury, Stéphanie / Duboisset, Elodie / Ayllon Ugarte, Jorge / Rami, Dalilia / Saler, Christine / Reinbolt, Manon / Le Fevre, Clara / Ben Abdelghani, Meher / Dourthe, Louis-Marie / Perruisseau-Carrier, Joffrey / Nguimpi-Tambou, Marlène / Barret, Flavie / Di Stefano Anna, Luisa / Balthazard, Annie / Vassord-Dang, Camille / Le Marchand, Mathilde / Vergniol, Julien / Pripon, Iulia / Daemaegdt, Axelle / Latry, Vanessa / Larrieu, Muna / Landry, Gaëlle / Touihri Maximin, Laetitia / Del Piano, Francesco / Barlet, Agnès / Vernisse, Mylène / Lafond, Sophie / Genin, Charline / Sibertin-Blanc, Camille / Chabrillac, Emilien / Gregoire, Caroline / Vergez, Sébastien / Panouille, Quentin / Guimbaud, Rosine / Richa, Floriane / Lebellec, Loïc / Gounin, Sophie / Buiret, Guillaume / Baudin, Marine / Hamon, Hervé / Deshorgue, Anne-Claire / Barrascout, Eduardo / Legrand, Stéphanie / Houlze, Morgane / Cambula, Linda / Lopez, Anthony / Fouquet, Guillaume / Touabi, Kahina / GermaIn, Adeline / Godbert, Benoit / Voivret, Florence / Perrin, Julie / Da Silva, Rosa / Bernichon, Emilie

European Journal of Cancer

A French nationwide cohort study (GCO-002 CACOVID-19)

2020 Volume 141, Page(s) 62–81

Keywords	Cancer Research ; Oncology ; covid19
Language	English
Publisher	Elsevier BV
Publishing country	us
Document type	Article ; Online
ZDB-ID	82061-1
ISSN	1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
ISSN (online)	1879-0852
ISSN	0277-5379 ; 0959-8049 ; 0964-1947
DOI	10.1016/j.ejca.2020.09.035
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

In stock of ZB MED Cologne/Königswinter

Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 583: Show issues

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito